1. Scrip

Oncology Accelerates In China As Large Makers Hunt For Assets

Half Of IND Filings

 
• By Brian Yang

New regulatory measures shorten clinical trial approval times and usher in busy deal-making between large makers and smaller biotechs outside China.

venture capital
ONCOLOGY APPROVALS ACCELERATING AS CHINESE DRUG MAKERS HUNT FOR DEALS • Source: Alamy

The latest announcement regarding a tie-up between Qilu Pharmaceutical Co., Ltd., a major Chinese active ingredient maker, and US biotech Sesen Bio, Inc. is aimed at accelerating the bladder cancer drug Vicinium in China.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By Lisa Takagi

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.

AstraZeneca Logs Japan Growth Despite Price Cuts

 
• By Lisa Takagi

AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By Jung Won Shin

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.